[go: up one dir, main page]

PE20221004A1 - Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados - Google Patents

Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados

Info

Publication number
PE20221004A1
PE20221004A1 PE2021002191A PE2021002191A PE20221004A1 PE 20221004 A1 PE20221004 A1 PE 20221004A1 PE 2021002191 A PE2021002191 A PE 2021002191A PE 2021002191 A PE2021002191 A PE 2021002191A PE 20221004 A1 PE20221004 A1 PE 20221004A1
Authority
PE
Peru
Prior art keywords
cdr2
cdr1
cdr3
antibody
comprises seq
Prior art date
Application number
PE2021002191A
Other languages
English (en)
Inventor
Jan-Willem Theunissen
Allen G Cai
Thi-Sau Migone
Original Assignee
Iconic Therapeutics Inc
Zymeworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iconic Therapeutics Inc, Zymeworks Inc filed Critical Iconic Therapeutics Inc
Publication of PE20221004A1 publication Critical patent/PE20221004A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente documento define un conjugado anticuerpo y farmaco que comprende: a. una proteina de union al antigeno (Ab) que se une al domino extracelular del factor tisular (TF) humano (SEQ ID n.º: 810), donde el Ab comprende una VHCDR1, una VH-CDR2, una VH-CDR3, una VL-CDR1, una VL-CDR2 y una VLCDR3, donde i. la VH-CDR1 comprende la SEQ ID n.°: 872, la VH-CDR2 comprende la SEQ ID n.°: 873, la VH-CDR3 comprende la SEQ ID n.°: 874, la VL-CDR1 comprende la SEQ ID n.°: 875, la VL-CDR2 comprende la SEQ ID n.°: 876 y la VL-CDR3 comprende la SEQ ID n.°: 877, ii. la VH-CDR1, la VH-CDR2, la VH-CDR3, la VL-CDR1, la VL-CDR2 y la VLCDR3 son del anticuerpo designado 25A3, iii. la VH-CDR1, la VH-CDR2, la VH-CDR3, la VL-CDR1, la VL-CDR2 y la VLCDR3 son del anticuerpo designado 25A, iv. la VH-CDR1, la VH-CDR2, la VH-CDR3, la VL-CDR1, la VL-CDR2 y la VLCDR3 son del anticuerpo designado 25A5, v. VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 y VL-CDR3 son del anticuerpo designado 25A5-T o vi. VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 y VL-CDR3 son del anticuerpo designado 25G1; y b. una o mas fracciones de toxinas y conectores representados por la Formula IV, en donde; X es -C(O)NHCH(CH2(R2 ))-+ , donde y + representan los respectivos puntos de union, como se indica en la Formula IV, o X esta ausente; L es un conector; ! representa el punto de union de L con el Ab, donde L se une al Ab mediante un enlace covalente; R1 se selecciona del grupo que consiste en ( ) donde # y % representan los respectivos puntos de union, como se indica en la Formula IV y R2 es fenilo. En el presente documento se proporcionan anticuerpos que se unen especificamente al factor tisular (TF) humano, conjugados de anticuerposfarmacos (ADC) antiTF y composiciones que comprenden a los anticuerpos o ADC.
PE2021002191A 2019-07-03 2020-07-02 Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados PE20221004A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962870644P 2019-07-03 2019-07-03
PCT/US2020/040711 WO2021003399A1 (en) 2019-07-03 2020-07-02 Anti-tissue factor antibody-drug conjugates and related methods

Publications (1)

Publication Number Publication Date
PE20221004A1 true PE20221004A1 (es) 2022-06-15

Family

ID=74100836

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021002191A PE20221004A1 (es) 2019-07-03 2020-07-02 Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados

Country Status (21)

Country Link
US (1) US20220257789A1 (es)
EP (1) EP3994150A4 (es)
JP (1) JP7709636B2 (es)
KR (1) KR20220029724A (es)
CN (1) CN114222752B (es)
AR (1) AR119346A1 (es)
AU (1) AU2020299398C1 (es)
BR (1) BR112021025720A2 (es)
CA (1) CA3141428A1 (es)
CL (2) CL2021003414A1 (es)
CO (1) CO2022001083A2 (es)
CR (1) CR20220047A (es)
DO (1) DOP2021000268A (es)
EA (1) EA202193309A1 (es)
EC (1) ECSP22007981A (es)
IL (1) IL289138A (es)
MX (1) MX2021015974A (es)
PE (1) PE20221004A1 (es)
PH (1) PH12021553289A1 (es)
TW (1) TWI879780B (es)
WO (1) WO2021003399A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7653013B2 (ja) 2018-01-04 2025-03-28 アイコニック セラピューティクス リミテッド ライアビリティ カンパニー 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
TW202342517A (zh) * 2022-01-12 2023-11-01 美商艾康尼醫療有限責任公司 使用抗組織因子抗體之炎性疾病治療
US20250333541A1 (en) * 2022-02-24 2025-10-30 Evopoint Biosciences Co., Ltd. Antibody, and drug conjugate and use thereof
TW202345906A (zh) * 2022-03-09 2023-12-01 美商艾克塞里克斯公司 以抗組織因子抗體藥物結合物治療實體腫瘤之方法
US20250276077A1 (en) * 2022-04-05 2025-09-04 Immunome, Inc. Epha2 antibodies
CN116143929B (zh) * 2023-02-03 2023-08-01 北京基科晟斯医药科技有限公司 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用
CN116789837B (zh) * 2023-03-24 2024-02-23 山西纳安生物科技股份有限公司 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用
CN118772282A (zh) * 2023-04-10 2024-10-15 复旦大学 靶向组织因子的纳米抗体及偶联物的制备方法和用途
CN121039165A (zh) * 2023-04-28 2025-11-28 江苏恒瑞医药股份有限公司 抗tf抗体和抗tf抗体-药物偶联物及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700547T1 (it) * 2010-06-15 2018-01-11 Genmab As Coniugati di farmaco anticorpo umano contro il fattore tissutale
KR102494557B1 (ko) 2014-09-17 2023-02-02 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
LT3280441T (lt) * 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
UA128472C2 (uk) * 2017-08-25 2024-07-24 Файв Прайм Терапеутікс Інк. B7-h4 антитіла і методи їх використання
KR20250044949A (ko) 2017-11-02 2025-04-01 젠맵 에이/에스 항-조직 인자 항체-약물 접합체 및 암 치료에서의 그의 용도
CN111727075B (zh) * 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
JP7653013B2 (ja) * 2018-01-04 2025-03-28 アイコニック セラピューティクス リミテッド ライアビリティ カンパニー 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
TWI841554B (zh) * 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
BR112022025105A2 (pt) * 2020-06-29 2023-01-17 Genmab As Método para o tratamento de câncer cervical em um indivíduo, conjugado anticorpo-fármaco, e, uso de um conjugado anticorpo-fármaco

Also Published As

Publication number Publication date
CN114222752A (zh) 2022-03-22
EP3994150A4 (en) 2023-08-02
IL289138A (en) 2022-02-01
EA202193309A1 (ru) 2022-03-28
MX2021015974A (es) 2022-04-26
KR20220029724A (ko) 2022-03-08
ECSP22007981A (es) 2022-05-31
CL2021003414A1 (es) 2022-09-09
JP2022538908A (ja) 2022-09-06
TWI879780B (zh) 2025-04-11
EP3994150A1 (en) 2022-05-11
PH12021553289A1 (en) 2022-08-01
WO2021003399A1 (en) 2021-01-07
BR112021025720A2 (pt) 2022-06-21
CL2024003094A1 (es) 2025-02-07
US20220257789A1 (en) 2022-08-18
CA3141428A1 (en) 2021-01-07
AU2020299398C1 (en) 2025-10-02
CO2022001083A2 (es) 2022-05-20
AU2020299398A1 (en) 2022-02-24
CR20220047A (es) 2022-06-23
TW202116357A (zh) 2021-05-01
DOP2021000268A (es) 2022-08-15
AR119346A1 (es) 2021-12-09
JP7709636B2 (ja) 2025-07-17
CN114222752B (zh) 2025-11-14

Similar Documents

Publication Publication Date Title
PE20221004A1 (es) Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados
CN111867630B (zh) 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
JP6727379B2 (ja) Ｈｅｒ２を標的とする二重特異性抗原結合性コンストラクト
CA2964830C (en) Anti-tim3 antibodies and methods of use
ES2784685T3 (es) Productos conjugados de anticuerpo-fármaco específicos de AXL para el tratamiento del cáncer
DK3102606T3 (en) ANTIBODY MEDICINAL CONJUGATES AND IMMUNTOXINES
UA116874C2 (uk) Імунокон'югат анти-мезотеліну
PE20091112A1 (es) Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo
MX2023008339A (es) Conjugados anticuerpo-fármaco de camptotecina y métodos de uso de estos.
PH12020500417A1 (en) Anti-efgr antibody drug conjugates (adc) and uses thereof
JP6872482B2 (ja) Ｈｅｒ２を標的とする二重特異性抗原結合性構築物の使用方法
ES2633297T3 (es) Anticuerpos monoclonales al factor básico de crecimiento de fibroblastos
CO6290705A2 (es) Anticuerpos monoclonales aislados o porciones de union a antigenos, que se unen especificamente a la integrina alfa 5-beta1, y composiciones farmaceuticamente aceptables de los mismos
CN104755499B (zh) 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白
BRPI0719762B8 (pt) anticorpo humano isolado, composição, polinucleotídeo isolado, vetor de expressão, microrganismo isolado, método para fabricação de um anticorpo, e, uso de um anticorpo
JP2024500242A (ja) 腫瘍特異的クローディン１８．２抗体と薬物との複合体
CN105949313A (zh) 抗体Fc变体
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
ES2668645T3 (es) Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B
JP2023505318A (ja) ヒト化ｃｌｄｎ１８．２抗体
JP2023509402A (ja) 新規抗ＦＧＦＲ２ｂ抗体
PE20220217A1 (es) Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso
PE20221459A1 (es) Conjugados anticuerpo-farmaco dirigido a claudina 18.2
JP2023508173A (ja) 新規抗ＦＧＦＲ２ｂ抗体
PE20220566A1 (es) ANTICUERPOS DE UNION A VISTA A pH ACIDO